Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
9 hedge funds and large institutions have $110K invested in Sonnet BioTherapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, reducing their positions, and 14 closing their positions.
0.15% more ownership
Funds ownership: 0.12% → 0.27% (+0.15%)
57% less funds holding
Funds holding: 21 → 9 (-12)
86% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 14
95% less capital invested
Capital invested by funds: $2.11M → $110K (-$2M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$90.6K |
| 2 |
Renaissance Technologies
New York
|
+$37.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$24.4K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$946 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$630 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.61M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$83K |
| 3 |
State Street
Boston,
Massachusetts
|
-$46.3K |
| 4 |
VF
Virtu Financial
New York
|
-$42K |
| 5 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$35K |
SONN Hedge Fund Activity: Q3 2023 in Review
9 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q3 2023, worth a combined $110K — down 95% from $2.11M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of SONN and 2 opened new positions — a net loss of 12 holders — while 0 trimmed existing stakes and 3 added.
The largest buyer was Vanguard Group, adding an estimated $90.6K. The largest seller was Sabby Management, exiting entirely with an estimated $1.61M sold.
- 9 institutional investors held Sonnet BioTherapeutics (SONN) as of Q3 2023, down from 21 in Q2 2023.
- Funds reported $110K of Sonnet BioTherapeutics stock for Q3 2023, down 95% quarter-over-quarter.
- 2 funds opened new Sonnet BioTherapeutics positions in Q3 2023 and 14 closed out, a net change of -12 holders.
- The largest Sonnet BioTherapeutics buyer in Q3 2023 was Vanguard Group, an estimated $90.6K added.
- The largest Sonnet BioTherapeutics seller in Q3 2023 was Sabby Management, an estimated $1.61M sold.
Based on aggregated 13F filings for Q3 2023.